ArticleCell death discovery2026
Mesenchymal stem cell-derived small extracellular vesicles suppress pyroptosis by delivering miR-125a-5p to improve acute kidney injury in sepsis.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Sepsis-induced acute kidney injury (S-AKI) is a life-threatening condition driven by excessive immune inflammation, and effective treatments remain lacking. Mesenchymal stem cell-derived small extracellular vesicles (MSC-sEV) have been demonstrated to possess potent immunomodulatory activity. This study aimed to investigate the role and underlying mechanism of MSC-sEV in S-AKI. We established in vivo and in vitro models of S-AKI and employed techniques such as small RNA sequencing, transcriptome sequencing, luciferase reporter assays, and engineered gene editing to validate therapeutic efficacy and elucidate mechanisms. Results demonstrated that in S-AKI, MSC-sEV homed to injured kidneys and were internalized by renal tubular epithelial cells, significantly ameliorating renal damage and improving survival rates. Mechanistically, MSC-sEV delivered miR-125a-5p to target and inhibit TNFR2 expression, thereby blocking TNF-driven pyroptosis mediated by the NF-κB/NLRP3 signaling pathway. Furthermore, engineered modification with the EXOMotif GGAG significantly enhanced MSC-sEV delivery of miR-125a-5p and inhibition of TNFR2. In conclusion, this study demonstrates that MSC-sEV represent a promising drug delivery vehicle with substantial targeted therapeutic potential for S-AKI.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.